DWA
ACRS icon

Dorsey Wright & Associates’s Aclaris Therapeutics ACRS Stock Holding History

Dorsey Wright & Associates’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,110
Closed -$154K – 289
2021
Q1 		$154K Buy
6,110
+3,510
+135% +$68.6K 1.81% 5
2020
Q4 		$17K Buy
+2,600
New +$11K ﹤0.01% 192

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Dorsey Wright & Associates's ACRS Position: Q2 2021 in Review

Dorsey Wright & Associates sold out of Aclaris Therapeutics (ACRS) in Q2 2021, closing a stake of 6,110 shares — an estimated $154K sold.

Dorsey Wright & Associates first reported a position in ACRS in Q4 2020 and held it in 2 quarters. The position peaked at $154K in Q1 2021. 128 funds tracked by Wall St. Rank hold ACRS as of Q2 2021.

  • Dorsey Wright & Associates reported no remaining Aclaris Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 6,110 Aclaris Therapeutics shares in Q2 2021, an estimated $154K.
  • Dorsey Wright & Associates first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's Aclaris Therapeutics position peaked at $154K in Q1 2021.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2021.

Based on Dorsey Wright & Associates's 13F filing for Q2 2021, filed 23 Jul 2021.